Investors

SciFluor Life Sciences launched in February 2011 with a $5 million funding commitment from Allied Minds. Allied Minds is a private investment firm that deploys capital to form, fund, manage and build companies based on market-creating technologies developed at renowned U.S. universities and federal research institutions. More information about the Boston-based company can be found at www.alliedminds.com

Invesco Asset Management

www.invesco.com

Woodford Patient Capital Trust

www.woodfordfunds.com

SciFluor News

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
read more >

SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
read more >

SciFluor Life Sciences Awarded Second U.S. Patent for Integrin αvβ3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
read more >

SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
read more >

SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
read more >

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders
read more >